Table 2.

Adjusted logistic regression model of factors associated with nodal pathologic complete response among patients with clinically node positive breast cancer after neoadjuvant chemotherapy

	ORa	95% CIb	p-value
Age	0.99	[0.99 – 0.99]	<0.001
Race (ref: white)
Black	0.90	[0.85 – 0.95]	<0.001
Other	1.16	[0.82 – 1.65]	0.41
Place of residence (ref: metro/urban)
Rural	1.11	[0.92 – 1.34]	0.29
Insurance status (ref: not insured)
Insured	1.03	[0.90 – 1.18]	0.68
Facility type (ref: academic/research)
Community Programs	0.91	[0.86 – 0.96]	<0.001
Integrated Network Cancer Program	0.97	[0.91 – 1.03]	0.30
CCIc (ref: 0)
1	0.96	[0.89 – 1.03]	0.22
>1	0.85	[0.74 – 0.96]	0.012
Subtype of breast cancer (ref: TNBCc)
ER+/HER2+	0.91	[0.81 – 1.01]	0.08
ER+/HER2−	0.41	[0.38 – 0.44]	<0.001
ER−/HER2+	1.32	[1.21 – 1.44]	<0.001
Endocrine therapy (ref: no)
Yes	0.74	[0.68 – 0.81]	<0.001
Immunotherapy (ref: no)
Yes	1.60	[1.46 – 1.74]	<0.001
cT (ref: cT0)
1	1.09	[0.72 – 1.64]	0.70
2	1.05	[0.69 – 1.58]	0.83
3	0.90	[0.59 – 1.36]	0.62
4	0.78	[0.52 – 1.18]	0.24
cN (ref: cN1)
2	0.76	[0.71 – 0.82]	<0.001
3	0.79	[0.73 – 0.87]	<0.001
Histology (ref: ductal)
Lobular	0.62	[0.54 – 0.73]	<0.001
Other	0.75	[0.69 – 0.82]	<0.001
Grade (ref: 1)
2	1.45	[1.21 – 1.72]	<0.001
3	2.32	[1.95 – 2.76]	<0.001

^aOdds ratio

^bConfidence interval

^cTriple negative breast cancer